{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:35:05Z","timestamp":1791668105827,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jcf.2020.09.008","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T02:42:47Z","timestamp":1601520167000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-4693","authenticated-orcid":false,"given":"James F.","family":"Chmiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-6879","authenticated-orcid":false,"given":"Patrick","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian G.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen J.","family":"Dozor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Sapiejka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rachel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Dgetluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2323-442X","authenticated-orcid":false,"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2020.09.008_bib0001","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"issue":"Suppl 40","key":"10.1016\/j.jcf.2020.09.008_bib0002","first-page":"S39","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50","author":"Nichols","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"S3","key":"10.1016\/j.jcf.2020.09.008_bib0003","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ppul.24129","article-title":"Inflammation in cystic fibrosis: an update","volume":"53","author":"Roesch","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2020.09.008_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.09.008_bib0005","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcf.2017.04.005","article-title":"Standardized treatment of pulmonary exacerbations (STOP) study: observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations","volume":"16","author":"Sanders","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.09.008_bib0006","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jcf.2015.01.007","article-title":"Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients","volume":"14","author":"Waters","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.09.008_bib0007","doi-asserted-by":"crossref","first-page":"1940\u20108","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2020.09.008_bib0008","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2020.09.008_bib0009","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1016\/j.jcf.2020.09.008_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1016\/j.jcf.2020.09.008_bib0011","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1164\/rccm.201608-1678LE","article-title":"Patients with cystic fibrosis and a G551D or homozygous F508del mutation: similar lung function decline","volume":"195","author":"Sawicki","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jcf.2020.09.008_bib0012","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2020.09.008_bib0013","unstructured":"Cystic Fibrosis Foundation Patient Registry, Bethesda, Maryland, 2012."},{"key":"10.1016\/j.jcf.2020.09.008_bib0014","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1378\/chest.115.4.1053","article-title":"The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes","volume":"115","author":"Oermann","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2020.09.008_bib0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/17476348.2018.1483723","article-title":"Unmet needs in cystic fibrosis: the next steps in improving outcomes","volume":"12","author":"West","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2020.09.008_bib0016","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcf.2013.12.009","article-title":"A randomized double blind, placebo controlled Phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis","volume":"13","author":"Konstan","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.09.008_bib0017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2014.02.009","article-title":"Proresolving lipid mediators and mechanisms in the resolution of acute inflammation","volume":"40","author":"Buckley","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jcf.2020.09.008_bib0018","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.bmc.2014.04.062","article-title":"Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity","volume":"22","author":"Tepper","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jcf.2020.09.008_bib0019","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1096\/fj.08-118323","article-title":"Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4","volume":"23","author":"Zurier","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.jcf.2020.09.008_bib0020","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jcf.2020.09.008_bib0021","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcf.2020.09.008_bib0022","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2020.09.008_bib0023","article-title":"Resunab benefits in the murine mode of CF lung infection and inflammation without jeopardizing resolution of Pseudomonas aeruginosa (PA) colonization in the lung","author":"Bonfield","year":"2015","journal-title":"Cyst Fibros Found Res Conf"},{"key":"10.1016\/j.jcf.2020.09.008_bib0024","series-title":"Methods of assessing the reinforcing properties of abused drugs","first-page":"489","article-title":"Addiction Research Center Inventory (ARCI): measurement of euphoria and other drug effects","author":"Haertzen","year":"1987"},{"key":"10.1016\/j.jcf.2020.09.008_bib0025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2020.09.008_bib0026","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2020.09.008_bib0027","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s11136-011-0091-5","article-title":"Erratum to: psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample","volume":"21","author":"Quittner","year":"2012","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jcf.2020.09.008_bib0028","article-title":"Antibiotic and anti-inflammatory therapies for cystic fibrosis","volume":"3","author":"Chmiel","year":"2013","journal-title":"Cold Spring Harbor"},{"key":"10.1016\/j.jcf.2020.09.008_bib0029","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.200609-1354OC","article-title":"Association between pulmonary function and sputum biomarkers in cystic fibrosis","volume":"175","author":"Mayer-Hamblett","year":"2007","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1016\/j.jcf.2020.09.008_bib0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ppul.21374","article-title":"Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis","volume":"46","author":"Sanders","year":"2011","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320308730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320308730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:44:12Z","timestamp":1761601452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199320308730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1569199320308730"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.09.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}